Treace Medical Concepts reported second quarter 2026 financial results on August 7, 2026. Revenue decreased 4% to $45.4 million from $47.4 million in the prior year period. The company posted a net loss of $(15.9) million, or $(0.24) per share, compared to a $(17.4) million loss in the same quarter last year. Adjusted EBITDA was $(3.5) million, slightly improved from $(3.6) million previously. Year-to-date cash usage decreased by 57% ($3.6 million), with total liquidity of $45.6 million as of June 30, 2026. Management raised full-year 2026 revenue guidance to a range of $204 million to $212 million and updated the expected Adjusted EBITDA loss range to $(3.0) million–$(5.0) million. The company operates in the medical technology industry, specializing in surgical treatments for bunions and foot deformities.